Physician
Hematology
Dr. Rainer Brachmann, MD
|
|
Give Review
Rainer Brachmann works in the field of Hematology. Rainer Brachmann is a published physician as well. He has 32 publications published. The latest was: Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.
Publications
- A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
- A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
- Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced So...
- p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5.
- Heterogeneous biomedical database integration using a hybrid strategy: a p53 cancer research database.
- Genome wide screens in yeast to identify potential binding sites and target genes of DNA-binding proteins.
- hADA2a and hADA3 are required for acetylation, transcriptional activity and proliferative effects of beta-catenin.
- Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53.
- MAGED2: a novel p53-dissociator.
- Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.
- Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants.
- Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
- Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylation.
- ATP, Cancer and p53.
- p53 mutants: the achilles' heel of human cancers?
- A global suppressor motif for p53 cancer mutants.
- Genetic strategies in Saccharomyces cerevisiae to study human tumor suppressor genes.
- Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites.
- hADA3 is required for p53 activity.
- Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.
- Tag games in yeast: the two-hybrid system and beyond.
- Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions.
- Dominant-negative p53 mutations selected in yeast hit cancer hot spots.
- Hydroxybenzoyl-CoA reductase: coupling kinetics and electrochemistry to derive enzyme mechanisms.
- [Psychoneural diseases as related to sex and age].
- [Epidemiology of emergencies in advanced age].
- Expression of c-sis and other cellular proto-oncogenes in human sarcoma cell lines and biopsies.
- [Current utilization of bed capacity in selected hospitals].
- Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors.
- Recombinant expression, biochemical characterization, and biological activities of the human MGSA/gro protein.
- [Administration of prostaglandin E1 in diabetics and non-diabetic patients with severe Fontaine stage IIb arterial occlusive disease].
Schools
LudwigMaximiliansUniversitaet Munchen Fachbereich Medizin
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
Johns Hopkins University -
Georgetown University Hospital -
Ludwig Maximilian University of Munich Faculty of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Steven M. Lipkin, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Dazhi Cen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Birbal S. Bhaskar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepa Jeyakumar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Van Etten, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian Kim, MD |
|
|
Dr. Chaitali S. Nangia, MD
This Doctor is OpenDoctor Recommended.
|